Entry into Underwriting Agreement
On December 8, 2022, Autolus Therapeutics plc (the Company) entered into an underwriting agreement (the Underwriting
Agreement) with Jefferies LLC, William Blair & Company, L.L.C. and Wells Fargo Securities, LLC as representatives of the several underwriters named therein (collectively, the Underwriters), in
connection with the issuance and sale by the Company in a public offering of 75,000,000 American Depositary Shares (ADSs) representing 75,000,000 ordinary shares at a public offering price of $2.00 per ADS, for total gross
proceeds of $150.0 million (the Offering). All ADSs sold in the Offering were offered by the Company. In addition, the Company has granted the Underwriters a 30-day option to
purchase up to an additional 11,250,000 ADSs at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on or about December 13, 2022, subject to customary closing conditions.
The Offering was made pursuant to the Companys effective shelf registration statement on Form F-3 (File No. 333-258556) filed on August 5, 2021, as supplemented by a preliminary prospectus supplement dated December 8, 2022, filed with the Securities and Exchange Commission on December 8, 2022, and
a final prospectus supplement dated December 8, 2022, filed with the Securities and Exchange Commission on December 9, 2022.
The Underwriting
Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as
amended, and other obligations of the parties and termination provisions. The foregoing description is not complete and does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its
entirety by reference to the Underwriting Agreement that is filed as Exhibit 1.1 to this Report on Form 6-K (the Report) and is incorporated by reference herein.
The legal opinion of Cooley (UK) LLP relating to the ordinary shares underlying the ADSs to be issued and sold in this Offering is filed as Exhibit 5.1 to
this Report and is incorporated by reference herein.
On December 8, 2022, the Company issued a press release announcing the pricing of the Offering.
A copy of this press release is filed as Exhibit 99.1 to this Report and is incorporated by reference herein.
The information contained in this
Report, including Exhibits 1.1 and 5.1 hereto, but excluding Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statements on Form F-3 (File Nos. 333-258556, 333-264304 and 333-264650) and Form S-8 (File Nos.
333-226457).
EXHIBITS